Riik: Ameerika Ühendriigid
keel: inglise
Allikas: NLM (National Library of Medicine)
Hydroquinone (UNII: XV74C1N1AE) (Hydroquinone - UNII:XV74C1N1AE)
Stratus Pharmaceuticals
Hydroquinone
Hydroquinone 30 mg in 1 mL
PRESCRIPTION DRUG
unapproved drug other
MELQUIN 3- HYDROQUINONE LIQUID STRATUS PHARMACEUTICALS _Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been_ _approved by FDA. For further information about unapproved drugs, click here._ ---------- MELQUIN-3 TOPICAL SOLUTION (HYDROQUINONE 3% SKIN BLEACHING TOPICAL SOLUTION) RX ONLY DESCRIPTION Each mL of MELQUIN-3 TOPICAL SOLUTION contains ACTIVE: Hydroquinone 3.0% (30 mg) INACTIVES: SD Alcohol 40B (45% by volume), Purified Water, Isopropyl Alcohol(4% by volume), Propylene Glycol, Laureth-4, Hydroxyethyl Cellulose and Ascorbic Acid. Hydroquinone is 1, 4-Benzenediol, with a chemical formula of C6H6O2 and a molecular weight of 110.11. The structural formula is: C H O CLINICAL PHARMACOLOGY Topical application of hydroquinones produce a reversible depigmentation of the skin by the inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) [Denton, C., et al , 1952 (1)] and suppression of other melanocyte metabolic processes [Jimbow, K., et al, 1974 (2)]. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas [Parrish, J., et al, 1978 (3)]. INDICATIONS AND USAGE MELQUIN-3 TOPICAL SOLUTION is indicated for the temporary bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines and other undesired areas of melanin hyperpigmentation. CONTRAINDICATIONS MELQUIN-3 TOPICAL SOLUTION is contraindicated in persons who have shown hypersensitivity to hydroquinone or any of the other ingredients. The safety of topical treatment of hydroquinone during pregnancy or in children (12 years and under) has not been established. (See PRECAUTIONS). ® ® 6 6 2 ® ® WARNINGS 1. Hydroquinone is a skin bleaching agent which may produce undesired effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication. 2. To evaluate possible susceptibility to irritation or sensitivity, each patient should begin Lugege kogu dokumenti